Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics

Adriana Velasova, Lucie Dlouha, Iva Hamova, Kristyna Kupcova, Petra Zemankova, Petr Nehasil, Jana Senavova, Katerina Benesova, Petra Svozilkova, Jarmila Heissigerova, Marek Trneny, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 2979.

https://doi.org/10.1182/blood-2024-211732

Published: 2024

Journal Articles

Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice

Iva Hamova, Prokop Vodicka, Adriana Velasova, Kristyna Kupcova, Petra Zemankova, Petr Nehasil, Anton Tkachenko, Kamila Polgarova, Jana Salkova, Katerina Benesova, Pavel Klener, Marek Trneny, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 6235.

https://doi.org/10.1182/blood-2024-211263

Published: 2024

Journal Articles

Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?

Liliana Tuskova, Diana Maláriková, Katerina Benesova, Eva Konirova, Kamila Polgarova, Petra Blahovcova, Jana Salkova, Marek Trněný, Pavel Klener

Blood (2024) 144 (Supplement 1): 3012.

https://doi.org/10.1182/blood-2024-198865

Published: 2024

Journal Articles

The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Andrea Hruskova, Heidi Mocikova, Juraj Duras, Katerina Steinerova, Alice Sykorova, Michal Masar, Jitka Dlouha, Petra Blahovcova, Marek Trneny

Blood (2024) 144 (Supplement 1): 1697.

https://doi.org/10.1182/blood-2024-208416

Published: 2024

Journal Articles

Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World

Michal Masar, Prokop Vodicka, Samuel Hricko, Andrea Janikova, Katerina Benesova, David Salek, Jana Salkova, Martina Filipova, Jan Galko, Vit Campr, Magdalena Klanova, Marek Trneny

Blood (2024) 144 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2024-208592

Published: 2024

Journal Articles

BMI and Its Changes As a Predictor of Survival in DLBCL Patients

Michal Masar, Prokop Vodicka, Magdalena Klanova, Kamila Polgarova, Katerina Benesova, Diana Malarikova, Jana Salkova, Jan Koren, Pavel Klener, Marek Trneny

Blood (2024) 144 (Supplement 1): 1713.

https://doi.org/10.1182/blood-2024-208542

Published: 2024

Journal Articles

PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Veronika Hanackova, Heidi Mocikova, Juraj Duras, Katerina Steinerova, Eva Konirova, Tomas Prochazka, Kamila Polgarova, Jitka Dlouha, Petra Blahovcova, Marek Trneny

Blood (2024) 144 (Supplement 1): 1711.

https://doi.org/10.1182/blood-2024-204795

Published: 2024

Journal Articles

DLBCL Patients' Journey: From Symptoms to Diagnosis

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Sarka Hrabetova, Jitka Dlouha, Marek Trněný

Blood (2023) 142 (Supplement 1): 3140.

https://doi.org/10.1182/blood-2023-186207

Published: 2023

Journal Articles

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Jitka Dlouha, Sarka Hrabetova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4510.

https://doi.org/10.1182/blood-2023-186467

Published: 2023

Journal Articles

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

Magdalena Klanova, Samuel Hricko, Michal Masar, David Salek, Prokop Vodicka, Natasa Kopalova, Petra Blahovcova, Katerina Benesova, Jozef Michalka, Jan Koren, Andrea Janikova, Marek Trneny

Blood (2023) 142 (Supplement 1): 4479.

https://doi.org/10.1182/blood-2023-178208

Published: 2023

Journal Articles

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

Prokop Vodicka, Andrea Janikova, David Belada, Heidi Mocikova, Vit Prochazka, Juraj Duras, Katerina Steinerova, Vit Campr, Katerina Benesova, Samuel Hricko, Alice Sykorova, Petra Blahovcova, Radek Jaksa, Magdalena Klanova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2023-185620

Published: 2023

Journal Articles

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Heidi Mocikova, Jan Pirnos, Vit Prochazka, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Petra Blahovcova, Vit Campr, Pavel Klener, Jr., Alice Sykorova, Marek Trneny

Blood (2022) 140 (Supplement 1): 3775–3776.

https://doi.org/10.1182/blood-2022-159408

Published: 2022

Journal Articles

Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy

Jana Karolova, Dmitry Kazantsev, Michael Svaton, Liliana Tušková, Kristina Forsterova, Diana Malarikova, Katerina Benesova, Tomáš Heizer, Alexandra Dolníková, Magdalena Klanova, Eva Fronkova, Marek Trněný, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 6409–6410.

https://doi.org/10.1182/blood-2022-166069

Published: 2022

Journal Articles

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Vít K Procházka, Štěpánka Matuštíková, Tomáš Fürst, Dr., David Belada, MD PhD, Andrea Janíková, MD PhD Assoc Prof, Kateřina Benešová, MD PhD, Heidi Mociková, MD, Juraj Ďuraš, MD, Jan Pirnos, MD, Kateřina Kopečková, MD PhD, Vít Campr, MD PhD, Jozef Michalka, MD, Robert Pytlík, MD, Tomáš Papajík, MD prof, Marek Trněný, MD prof

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139830

Published: 2020

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Journal Articles

Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry

Andrea Janikova, MD PhD, Assoc Prof, Robert Pytlik, MD, Pavel Klener, MD PhD, Zbynek Bortlicek, PhD, Vit Campr, MD PhD, Natasa Kopalova, Mgr, Katerina Benesova, MD PhD, Michaela Hamouzova, David Belada, MDPhD, Vit Prochazka, MD PhD ass. prof., Jan Pirnos, MD, Juraj Duras, MD, Heidi Mocikova, MD, PhD, Jiri Mayer, MD, Marek Trneny

Blood (2016) 128 (22): 3000.

https://doi.org/10.1182/blood.V128.22.3000.3000

Published: 2016

Journal Articles

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Marek Trneny, MD, Pavel Klener, MD, David Belada, MD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, Samuel Vokurka, MD PhD, Jan Pirnos, MD, Katerina Kubackova, MD, Juraj Duras, MD, Jana Salkova, MD, David Salek, MD, Robert Pytlik, MD, PhD, Lucie Barsova, MD, Petr Kessler, MD, Ludmila Boudova, MD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jitka Dlouha, Katerina Benesova, MD

Blood (2014) 124 (21): 4425.

https://doi.org/10.1182/blood.V124.21.4425.4425

Published: 2014

Journal Articles

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

Andrea Janikova, MD, PhD, Katerina Benesova, MD, Zbynek Bortlicek, Vit Campr, MD, Ph.D., Natasa Kopalova, David Belada, M.D., Ph.D., Vit Prochazka, M.D., Ph.D., Robert Pytlik, MD, Ph.D., Samuel Vokurka, MD, PhD, Jan Pirnos, MD, Milan Matuska, MD, PhD, Heidi Mocikova, MD, PhD, Jiri Mayer, MD, PhD, Marek Trneny, MD, Ph.D., Prof.

Blood (2013) 122 (21): 4388.

https://doi.org/10.1182/blood.V122.21.4388.4388

Published: 2013

Journal Articles

Factors Affecting Quality of Life During and After Stem Cell Transplantation in Long Term Survivors – Comparison of Autologous and Allogeneic Stem Cell Transplantation

Katerina Benesova, MD, Marie Trnkova, Mgr, Miriam Lanska, MD, Veronika Valkova, MD, Katerina Steinerova, MD, Zdenek Koristek, MD, Jan Novak, MD, Ludek Raida, MD, Petra Keslova, MD, Blanka Vackova, MD, Klara Kruntoradova, Ing, Tomas Dolezal, MD, Marek Trneny, MD

Blood (2012) 120 (21): 590.

https://doi.org/10.1182/blood.V120.21.590.590

Published: 2012

Journal Articles

Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma: Data from National Czech Registry.

Veronika Valkova, Antonin Vitek, Edgar Faber, Jiri Mayer, Pavel Zak, Katerina Benesova, Marek Trneny

Blood (2006) 108 (11): 5375.

https://doi.org/10.1182/blood.V108.11.5375.5375

Published: 2006

NARROW

Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics

Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice

Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?

The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years

Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World

BMI and Its Changes As a Predictor of Survival in DLBCL Patients

PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial

DLBCL Patients' Journey: From Symptoms to Diagnosis

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

Factors Affecting Quality of Life During and After Stem Cell Transplantation in Long Term Survivors – Comparison of Autologous and Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma: Data from National Czech Registry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only